JP2002514418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002514418A5 JP2002514418A5 JP2000548465A JP2000548465A JP2002514418A5 JP 2002514418 A5 JP2002514418 A5 JP 2002514418A5 JP 2000548465 A JP2000548465 A JP 2000548465A JP 2000548465 A JP2000548465 A JP 2000548465A JP 2002514418 A5 JP2002514418 A5 JP 2002514418A5
- Authority
- JP
- Japan
- Prior art keywords
- rank
- protein
- seq
- polypeptide
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 102000014128 RANK Ligand Human genes 0.000 description 6
- 108010025832 RANK Ligand Proteins 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 3
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000648503 Homo sapiens Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 102000053530 human TNFRSF11A Human genes 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8548798P | 1998-05-14 | 1998-05-14 | |
| US11083698P | 1998-12-03 | 1998-12-03 | |
| US60/110,836 | 1998-12-03 | ||
| US60/085,487 | 1998-12-03 | ||
| PCT/US1999/010588 WO1999058674A2 (en) | 1998-05-14 | 1999-05-13 | Method of inhibiting osteoclast activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002514418A JP2002514418A (ja) | 2002-05-21 |
| JP2002514418A5 true JP2002514418A5 (enExample) | 2006-06-29 |
Family
ID=26772773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548465A Pending JP2002514418A (ja) | 1998-05-14 | 1999-05-13 | 破骨細胞活性の阻害方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050089522A1 (enExample) |
| EP (2) | EP1076699B1 (enExample) |
| JP (1) | JP2002514418A (enExample) |
| AT (2) | ATE517916T1 (enExample) |
| AU (1) | AU762574B2 (enExample) |
| CA (1) | CA2328140C (enExample) |
| CY (1) | CY1111912T1 (enExample) |
| DE (1) | DE69939822D1 (enExample) |
| DK (1) | DK2009025T3 (enExample) |
| ES (1) | ES2317694T3 (enExample) |
| PT (1) | PT2009025E (enExample) |
| WO (1) | WO1999058674A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| PT1114864E (pt) * | 1996-12-13 | 2008-10-08 | Schering Corp | Antigénios de superfície de células de mamífero, reagentes relacionados |
| WO1999058674A2 (en) | 1998-05-14 | 1999-11-18 | Immunex Corporation | Method of inhibiting osteoclast activity |
| ATE497001T1 (de) | 1996-12-23 | 2011-02-15 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| JP3523650B2 (ja) | 1997-04-15 | 2004-04-26 | 三共株式会社 | 新規蛋白質及びその製造方法 |
| EA003636B1 (ru) * | 1997-04-16 | 2003-08-28 | Амген Инк. | Остеопротегеринсвязующие белки и рецепторы |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| AU7705098A (en) * | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
| CA2647796A1 (en) * | 1999-07-28 | 2001-02-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting osteoclast activity |
| US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| WO2002064782A2 (en) * | 2001-02-09 | 2002-08-22 | Maxygen Holdings Ltd. | Rank ligand-binding polypeptides |
| CA2441538A1 (en) * | 2001-03-22 | 2002-10-17 | Barnes-Jewish Hospital | Stimulation of osteogenesis using rank ligand fusion proteins |
| EP1385872A4 (en) * | 2001-05-11 | 2004-12-15 | Res Dev Foundation | NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS |
| DE02726901T1 (de) * | 2001-05-17 | 2004-07-15 | Immunex Corp., Seattle | Therapeutische verwendung von rang-antagonisten |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| WO2003065972A2 (en) * | 2001-10-12 | 2003-08-14 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds |
| AU2003243139B2 (en) | 2002-04-05 | 2007-06-21 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| AU2003242265A1 (en) * | 2002-06-07 | 2003-12-22 | Sankyo Company, Limited | Combined effects of therapeutic or preventive agent composition for bone breakage |
| TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| WO2008150025A1 (ja) * | 2007-06-05 | 2008-12-11 | Oriental Yeast Co., Ltd. | 新しい骨量増加薬 |
| JP6403999B2 (ja) * | 2014-06-05 | 2018-10-10 | 株式会社細川洋行 | レトルト包装用積層体及び容器 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150090A (en) * | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| DK0897983T3 (da) | 1991-10-25 | 2003-08-11 | Immunex Corp | Antistoffer mod CD40-L |
| US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| PT672141E (pt) * | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5741667A (en) | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| AU2363695A (en) | 1995-04-27 | 1996-11-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
| NZ311335A (en) * | 1995-06-07 | 1998-05-27 | Immunex Corp | Cd40l muteins and their use as ligands |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規ｄｎａ及びそれを用いた蛋白質の製造方法 |
| PT1114864E (pt) | 1996-12-13 | 2008-10-08 | Schering Corp | Antigénios de superfície de células de mamífero, reagentes relacionados |
| WO1998028423A2 (en) | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
| WO1999058674A2 (en) | 1998-05-14 | 1999-11-18 | Immunex Corporation | Method of inhibiting osteoclast activity |
| US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| ATE497001T1 (de) | 1996-12-23 | 2011-02-15 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| JP3523650B2 (ja) * | 1997-04-15 | 2004-04-26 | 三共株式会社 | 新規蛋白質及びその製造方法 |
| EA003636B1 (ru) * | 1997-04-16 | 2003-08-28 | Амген Инк. | Остеопротегеринсвязующие белки и рецепторы |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
| AU7469998A (en) | 1997-05-01 | 1998-11-24 | Amgen, Inc. | Chimeric opg polypeptides |
| AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
| JPH11266872A (ja) | 1998-03-20 | 1999-10-05 | Suntory Ltd | ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法 |
| US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
| HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
| KR20010085996A (ko) | 1999-09-03 | 2001-09-07 | 스티븐 엠. 오드레 | 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법 |
| AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
| WO2001062932A1 (en) | 2000-02-23 | 2001-08-30 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| AU2001288342A1 (en) | 2000-08-21 | 2002-03-04 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| AU2003243139B2 (en) | 2002-04-05 | 2007-06-21 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
-
1999
- 1999-05-13 WO PCT/US1999/010588 patent/WO1999058674A2/en not_active Ceased
- 1999-05-13 AU AU39888/99A patent/AU762574B2/en not_active Expired
- 1999-05-13 CA CA2328140A patent/CA2328140C/en not_active Expired - Lifetime
- 1999-05-13 DE DE69939822T patent/DE69939822D1/de not_active Expired - Lifetime
- 1999-05-13 EP EP99923021A patent/EP1076699B1/en not_active Expired - Lifetime
- 1999-05-13 ES ES99923021T patent/ES2317694T3/es not_active Expired - Lifetime
- 1999-05-13 AT AT08015570T patent/ATE517916T1/de active
- 1999-05-13 EP EP08015570A patent/EP2009025B1/en not_active Expired - Lifetime
- 1999-05-13 PT PT08015570T patent/PT2009025E/pt unknown
- 1999-05-13 JP JP2000548465A patent/JP2002514418A/ja active Pending
- 1999-05-13 AT AT99923021T patent/ATE412746T1/de not_active IP Right Cessation
- 1999-05-13 DK DK08015570.8T patent/DK2009025T3/da active
-
2004
- 2004-11-30 US US10/999,523 patent/US20050089522A1/en not_active Abandoned
-
2008
- 2008-06-11 US US12/137,397 patent/US7790684B2/en not_active Expired - Fee Related
-
2011
- 2011-10-06 CY CY20111100954T patent/CY1111912T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gray et al. | Cloning of the cDNA of a human neutrophil bactericidal protein: structural and functional correlations | |
| Choi-Miura et al. | Identification of the disulfide bonds in human plasma protein SP-40, 40 (apolipoprotein-J) | |
| Odermatt et al. | Repeating modular structure of the fibronectin gene: relationship to protein structure and subunit variation. | |
| KR960704038A (ko) | 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek) | |
| JP2002500886A5 (enExample) | ||
| CA2190371A1 (en) | Receptor for oncostatin m | |
| JP2019506166A5 (enExample) | ||
| CA2328140A1 (en) | Method of inhibiting osteoclast activity | |
| JP2002508183A5 (enExample) | ||
| JP2003510366A5 (enExample) | ||
| CA2641565A1 (en) | Nel-related proteins type 1 and 2, and polynucleotides encoding them | |
| EP1939293A3 (en) | Interferon-Like Protein ZCYTO21 | |
| JP2009529509A5 (enExample) | ||
| WO2000026244A3 (en) | A novel tumor necrosis factor family member, drl, and related compositions and methods | |
| RU2000103824A (ru) | Адипоцит-специфические белковые гомологи | |
| WO2002008426A3 (en) | Fh-binding protein of streptococcus pneumoniae | |
| JP2026035742A5 (enExample) | ||
| Kuo et al. | Orientation of type VI collagen monomers in molecular aggregates | |
| ATE301714T1 (de) | Insulinartigen wachstumsfaktor bindendes protein -3 variante | |
| JP2004505640A5 (enExample) | ||
| Hayashi et al. | Tetrahymena histone H3. Purification and two variant sequences | |
| JPH0222292A (ja) | 高カルシウム体液性因子拮抗薬 | |
| CA2375605A1 (en) | Peptide leukotriene receptor | |
| DE69732363D1 (de) | HUMANES THYMOSIN beta 15 GEN,PROTEIN UND DESSEN VERWENDUNGEN | |
| Rostagno et al. | Comparison of the fibrin-binding activities in the N-and C-termini of fibronectin |